Efficacy in high-risk hypertensive patients

Adalat GITS is effective in...

hypertensive patients with cardiovascular risk

A predefined analysis of the ACTION study stratified patients according to hypertensive status (BP ≥140/90 mmHg) at baseline.1 In patients who were hypertensive at baseline (n=3977), Adalat GITS was associated with a significant reduction of mean BP by the end of the study, from 151.3/84.8 mmHg to 136.8/77.8 mmHg (p<0.001).1
Adapted from Lubsen J, et al. J Hypertens. 2005;23:641-8.
  • The INSIGHT study randomised patients with primary hypertension and one or more prespecified cardiovascular (CV) risk factors, for treatment with Adalat GITS or co-amilozide.2 In a preplanned side-arm study, 149 patients underwent 24-hour ambulatory blood pressure monitoring in addition to the office measurement mandated in the main INSIGHT study3

  • The results showed that patients receiving Adalat GITS showed effective BP control (comparable to co-amilozide) over the 24 hour dosing period and over the course of the study (up to 4 years)3
**p<0.01 (between-group differences or vs pre-treatment)

hypertensive patients with diabetes

  • A subgroup analysis of data from the INSIGHT trial (n=6321) examined BP control and CV outcomes in the hypertensive patients with diabetes at baseline (n=1302)4
  • Adalat GITS was associated with effective BP lowering in hypertensive patients with diabetes4
  • The magnitude of the BP reduction seen with Adalat GITS in the diabetes group was comparable to that achieved with co-amilozide4
  • BP reductions in the diabetes group were similar to those seen in patients without diabetes at baseline4
*P<0.001 within-group comparisons

elderly patients with hypertension

  • The MATH study compared the efficacy and safety of Adalat GITS 30–180 mg/day in elderly (≥65 years; n=222) vs non-elderly (<65 years; n=933) patients with mild-to-moderate hypertension5
  • Patients were titrated over 1–6 weeks on Adalat GITS 30–180 mg to target BP(sitting DBP <90 mmHg; 10 mmHg decrease from baseline) and maintained at optimal dose for an additional 12 weeks5
  • Target BP was reached in 85% of elderly and 74% of non-elderly patients with hypertension5
  • The reduction in SBP was significantly greater in elderly compared to non-elderly patients (p<0.001)5
†DBP <90 mmHg and a 10 mmHg decrease.
*p<0.001 at the end of the 12 week maintenance period, compared with baseline.

patients with isolated systolic hypertension (ISH)

  • A subgroup analysis of data from the INSIGHT trial (n=6321) examined BP control and CV outcomes in the population segment with ISH at baseline (n=1498)6
  • Adalat GITS was associated with effective BP lowering in patients with ISH6
  • Mean BP fell by 29/10 mmHg in the Adalat GITS group and 30/10 mmHg in the diuretic group, respectively, after a period up to 48 months treatment6
  • Other clinical outcomes occurred at comparable rates in the two groups6

References

  1. Lubsen J, et al. J Hypertens. 2005;23:641-8.
  2. Brown M, et al. Lancet. 2000;356:366-72.
  3. Mancia G, et al. J Hypertens 2002;20:545-53.
  4. Mancia G, et al. Hypertension 2003;41:431-6.
  5. Bravo EL, et al. Am J Hypertens 1990;3:326S-32S.
  6. Mancia G, et al. Blood Press 2004;13:310-5.